College of Nursing/The Research Institute of Nursing Science, Seoul National University, 28 Yeongeon-dong, Jongro-gu, Seoul, Republic of Korea.
BMC Cardiovasc Disord. 2013 Aug 8;13:55. doi: 10.1186/1471-2261-13-55.
Acute coronary syndrome (ACS) is highly prevalent in Korea and is the third-leading cause of death in Korea; however, the economic cost of ACS on Korean society has not been investigated. This study examined the economic effect of ACS on the Korean population during the period 2004 to 2009.
The analysis used the cost of illness (COI) framework. Data on direct medical costs, direct non-medical costs, and productivity loss related to ACS morbidity and mortality were included. The Korean National Health Insurance Corporation's claim database was used to obtain data on annual healthcare utilization and expenditures for the entire South Korean population. By using a data mining technique, we identified healthcare claims with ACS-related disease codes. Costs were estimated by using a macro-costing method.
In 2009, the prevalence of ACS in Korea was 6.4 persons per 1,000 population members and the associated mortality rate was 20.2 persons per 100,000 population members. The total cost of ACS in 2009 was USD 918.2 million. Of the total, direct medical cost was USD 425.3 million, direct non-medical cost was USD 11.4 million, and cost associated with morbidity and mortality was USD 481.5 million.
The results show that the total cost of ACS to the Korean society is high. Early and effective management of ACS is required to reduce ACS-associated mortality and morbidity. We suggest that further research be undertaken to determine ways to reduce the economic effects of ACS and its treatment.
急性冠状动脉综合征(ACS)在韩国的发病率很高,是韩国的第三大死因;然而,ACS 给韩国社会带来的经济成本尚未得到调查。本研究调查了 2004 年至 2009 年期间 ACS 对韩国人口的经济影响。
该分析使用了疾病经济负担(COI)框架。包括与 ACS 发病率和死亡率相关的直接医疗成本、直接非医疗成本和生产力损失的数据。使用韩国国民健康保险公司的索赔数据库获取了整个韩国人口的年度医疗保健利用和支出数据。通过使用数据挖掘技术,我们确定了与 ACS 相关疾病代码的医疗保健索赔。使用宏观成本核算方法估算成本。
2009 年,韩国 ACS 的患病率为每 1000 名居民中有 6.4 人,死亡率为每 10 万人中有 20.2 人。2009 年 ACS 的总成本为 9182 万美元。其中,直接医疗费用为 4253 万美元,直接非医疗费用为 1140 万美元,发病率和死亡率相关成本为 4815 万美元。
研究结果表明,ACS 给韩国社会带来的总成本很高。需要对 ACS 进行早期和有效的管理,以降低 ACS 相关的死亡率和发病率。我们建议进一步研究确定降低 ACS 及其治疗经济影响的方法。